Status:
COMPLETED
Study to Evaluate MET642 in Patients With NASH
Lead Sponsor:
Metacrine, Inc.
Conditions:
NASH - Nonalcoholic Steatohepatitis
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
Brief Summary
A randomized, double-blind, placebo-controlled study to evaluate MET642 in NASH patients.
Eligibility Criteria
Inclusion
- Diagnosis of NASH via biopsy, magnetic resonance elastography (MRE), or transient elastography (TE, FibroScan)
- Liver fat content ≥ 10% as measured by magnetic resonance imaging-proton density fat fraction (MRI-PDFF).
Exclusion
- History of significant liver disease (eg, alcoholic liver disease, viral hepatitis, etc.) or liver transplant.
- Presence of cirrhosis on any prior liver biopsy (stage 4 fibrosis).
- Excessive consumption of alcohol.
Key Trial Info
Start Date :
March 3 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 31 2022
Estimated Enrollment :
215 Patients enrolled
Trial Details
Trial ID
NCT04773964
Start Date
March 3 2021
End Date
December 31 2022
Last Update
March 28 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Pinnacle Research
San Antonio, Texas, United States, 78229